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Abstract: Neuropathic orofacial pain (NOP) is a debilitating condition. Although the pathophysiology
remains unclear, accumulating evidence suggests the involvement of multiple mechanisms in the
development of neuropathic pain. Recently, glial cells have been shown to play a key pathogenetic
role. Nerve injury leads to an immune response near the site of injury. Satellite glial cells are
activated in the peripheral ganglia. Various neural and immune mediators, released at the central
terminals of primary afferents, lead to the sensitization of postsynaptic neurons and the activation of
glia. The activated glia, in turn, release pro-inflammatory factors, further sensitizing the neurons,
and resulting in central sensitization. Recently, we observed the involvement of glia in the alteration of
orofacial motor activity in NOP. Microglia and astroglia were activated in the trigeminal sensory and
motor nuclei, in parallel with altered motor functions and a decreased pain threshold. A microglial
blocker attenuated the reduction in pain threshold, reduced the number of activated microglia,
and restored motor activity. We also found an involvement of the astroglial glutamate–glutamine
shuttle in the trigeminal motor nucleus in the alteration of the jaw reflex. Neuron–glia crosstalk thus
plays an important role in the development of pain and altered motor activity in NOP.
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1. Introduction
Chronic pain is a major public health problem that has a significant impact on both the individual
and community [1,2]. Acute pain is beneficial as it warns against impending or current tissue damage,
whereas in contrast, there appear to be no beneficial functions of chronic pain [3]. Neuropathic pain,
a type of chronic pain, can result from nerve injury, inflammation, or diseases of the peripheral or
central nervous systems, and is characterized by spontaneous pain (ongoing or episodic), pain resulting
from stimuli that would not normally provoke pain (allodynia), and exaggerated pain responses
to noxious stimuli (hyperalgesia) [3,4]. Neuropathic pain in the head, neck, face, oral or perioral
regions is termed neuropathic orofacial pain (NOP) [3–5]. The etiology of NOP can include systemic
diseases (e.g., diabetes), viral infections (e.g., herpes zoster), nerve compression, and injury to
peripheral nerves during dental operative procedures, such as tooth extraction, root canal treatment
and dental implant surgery [6,7]. Neuropathic pain is associated with dysfunction throughout the
pain pathway, including the nociceptors, the peripheral ganglia, the brainstem or the spinal cord,
Int. J. Mol. Sci. 2017, 18, 2051; doi:10.3390/ijms18102051 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2017, 18, 2051 2 of 17
the thalamus, and the cerebral cortex [8–12]. Neuropathic pain also causes motor impairment or
dysfunction [13–15]. However, the mechanisms of neuropathic pain are complex, rendering it difficult
to treat effectively [8–12].
Recent studies strongly suggest that the activation of glia in the pain transmission pathway plays
a critical role in the initiation and maintenance of neuropathic pain [16–19]. In this review, we discuss
the role of glia in the development of neuropathic pain and their involvement in the modulation of
orofacial motor activity in the disorder.
2. Chronic Orofacial Pain
Chronic orofacial pain is a major health problem, and is associated with high morbidity and
health service utilization [20,21]. The prevalence of chronic orofacial pain is unclear, but several
studies suggest that it is approximately 7–11% [3,5,22–25]. Chronic orofacial pain conditions represent
a challenge to the clinician because of their complexity. The chronic pain can be musculoskeletal
(e.g., temporomandibular disorders, chronic orofacial muscle pain), neuropathic (e.g., trigeminal
neuralgia, post-traumatic trigeminal neuropathy, burning mouth syndrome, trigeminal post-herpetic
neuralgia, glossopharyngeal neuralgia), vascular (post-stroke pain), or facial pain with headache
(e.g., tension type headache, chronic/episodic migraine) [3,5,6,26–32]. The pain can be episodic
(e.g., trigeminal neuralgia) [7,28] or continuous (e.g., burning mouth syndrome, post-traumatic
trigeminal neuropathy) [14,29,30]. The chronic pain can also be associated with neuropathy, which is
characterized by skin and mucosal numbness in the regions innervated by the trigeminal nerve, and is
caused by trauma, autoimmune diseases (e.g., systemic scleroderma, Sjogren’s syndrome and multiple
sclerosis), infectious diseases (e.g., syphilis, leprosy and viral infections) or cancer in the orofacial
region [2].
3. Neuropathic Orofacial Pain
Neuropathic orofacial pain (NOP) is often challenging for dental clinicians to diagnose
and treat [2,6]. This condition can arise as the result of injury, inflammation or pathological
diseases of either the peripheral or central nervous systems, and is characterized by continuous
or episodic pain in orofacial regions [4,8–11]. This type of pain is often associated with hyperalgesia
(exaggerated responses to painful stimuli), allodynia (pain resulting from stimuli that would not
normally provoke pain), and abnormal pins-and-needles sensations [4,8–11]. Numerous clinical entities
fall within NOP, including trigeminal neuralgia, post-traumatic trigeminal pain, atypical odontalgia,
burning mouth syndrome and glossopharyngeal neuralgia [6,7,28–32]. Trigeminal neuralgia is
an episodic neuropathic pain condition, and sufferers often report this pain as a severe, lancinating,
electric shock-like pain [7,28]. The pain is often localized in areas innervated by the second and third
divisions of the trigeminal nerve, and can be provoked by light touch [7,28]. The most common cause
of trigeminal neuralgia is compression of the trigeminal nerve root by an overlying loop of an artery
or vein, resulting in demyelination of the trigeminal sensory fibers [7,28]. In trigeminal post-herpetic
neuralgia, continuous pain occurs in extraoral and intraoral areas, at the sites of infection of herpes
zoster [32]. Burning mouth syndrome is an intraoral NOP condition, which manifests as a continuous
burning discomfort of the oral mucosa, especially the tongue [30]. Atypical odontalgia, or persistent
dentoalveolar pain, presents as localized pain in the dentoalveolar tissues. The pain may be a dull
throbbing continuous pain, and can sometimes be sharp [31]. Post-traumatic trigeminal neuropathy,
or peripheral painful traumatic trigeminal neuropathy (PPTTN), can be caused by nerve injury during
operative procedures, such as dental extraction, root canal filling, local anaesthetic injection and
implant placement, or facial trauma [3,14,29,33,34]. This type of NOP is increasingly common [6],
and is characterized by continuous burning, tingling and pins-and-needles-like pain in areas innervated
by the trigeminal nerve, including the tooth or tooth-bearing areas [3,14,29]. Patients with neuropathic
pain have psychological morbidity and a reduced quality of life [20]. They have reduced ability to
work and reduced mobility because of the pain. There is a substantial financial burden on society
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arising from direct costs for treatment, as well as from indirect costs associated with the loss of the
ability to work, the loss of the caregiver’s ability to work, and costs for living assistance [20,21].
4. Mechanisms of Neuropathic Orofacial Pain: Glial Involvement
The pathophysiological mechanisms underlying neuropathic pain are not fully understood.
Numerous studies suggest that the pathogenesis of neuropathic pain involves multiple complex
mechanisms [4,9,10,12]. Many studies on the mechanisms of neuropathic pain have used animal
models of injury to the peripheral nerve (e.g., injury to the sciatic nerve, or injury to the trigeminal
nerve, such as infraorbital or inferior alveolar nerve injury), which display some characteristic
features of neuropathic pain, such as allodynia and hyperalgesia [4,9,10,12]. Injury to the peripheral
nerve also causes motor dysfunction. For example, injury to the trigeminal system impairs
masticatory performance [6,13–15,20]. Multiple sites along the pain pathway are altered after nerve
injury [4,9,10,12]. Abnormalities such as spontaneous neural activity and ectopic sensitivity to stimuli
develop in the injured and uninjured afferents supplying the affected regions. There are changes in
the expression of various molecules in the injured and uninjured afferents, as well as in the ganglia
(dorsal root ganglia or trigeminal ganglia), where the cell bodies of afferents are located [4,8–12].
The sensitization of the peripheral nerves leads to central sensitization (sensitization occurs in neurons
present in the dorsal horn or in the brainstem trigeminal nuclei), resulting in an augmentation of the
response to peripheral stimuli (allodynia or hyperalgesia persist long after the injury to the peripheral
nerve) [4,8–12]. Recent studies suggest that the immune response to nerve injury, which is induced
both peripherally and centrally, plays an important role in the development and maintenance of
neuropathic pain [16–19]. Resident immune cells and neuroglia are activated, and immune cells from
the circulation are recruited in response to nerve injury [16–19].
Peripherally, nerve damage leads to activation of resident mast cells and macrophages and the
release of vasodilators (Figure 1), including vasoactive amines and bradykinin [16].
Blood borne immune cells, such as neutrophils, monocytes and T-lymphocytes, infiltrate the
site of injury [16]. Inflammatory mediators (Figure 1) are then released from these cells, and act on
receptors expressed on nerve terminals, leading to peripheral nociceptor sensitization [17]. In addition,
damaged peripheral nerves and Schwann cells release chemokines and cytokines, including tumor
necrosis factor alpha (TNF-α), interleukin-15 (IL-15) and interleukin-6 (IL-6), to facilitate the
recruitment of macrophages (Figure 1) [18]. The number of macrophages at the site of a spinal
nerve injury [35,36] or trigeminal nerve injury [37] is positively correlated with allodynia. IL-6 and
nerve growth factors are also increased after infraorbital nerve injury [38].
There is a strong correlation between released cytokines and chemokines at the site of nerve injury
and the initiation of neuropathic pain (for a detailed review, see [39,40]). Traditionally, cytokines and
chemokines are considered as proteins that regulate the immune response throughout the body.
Recent evidences suggest that cytokines and chemokines are released, not only from immune cells,
but also from neurons, at the site of the nerve injury. They participate in attracting more immune cells
to the site of the injury, to release inflammatory mediators. They also directly act on primary afferents
to increase their excitability. Complex interactions occur between various cell types and primary
afferent neurons at the site of injury that ultimately result in long-term changes in the excitability of
primary afferent neurons [39,40]. A neuropathic pain model, induced by a chronic constriction injury
to the sciatic nerve, showed that the cytokines, TNF-α and IL-1β, increased over ten-fold within 1 h in
the injured nerve [41]. In addition, inhibiting the action of TNF-α or IL-1β, attenuates the development
of chronic pain behavior, like mechanical allodynia and thermal hyperalgesia, in a variety of models
of neuropathic pain [42–45]. Chemokines released at the site of injury also play an important role
in the initiation of neuropathic pain. Monocyte chemoattractant protein-1 (MCP-1) or chemokine
ligand (CCL) 2 and its receptor, C-C chemokine receptor type 2 (CCR2) are upregulated in the primary
afferent neurons and Schwann cells of myelinated nerves in response to the nerve injury [46–50];
in turn, this excites the primary afferents as well as recruits more immune cells to the site of the
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nerve injury [51]. CCL3 is also upregulated in Schwann cells and in infiltrating macrophages close
to injured nerves, and participates in the initiation of neuropathic pain through its receptors CCR1
and CCR5 [40]. Injection of the chemokines—stromal cell-derived factor 1, (SDF1)/C-X-C motif
chemokine 12 (CXCL12) and macrophage inflammatory protein 1α (MIP-1α/CCL3)—into the adult
rat hind paw produces dose-dependent tactile allodynia [52], believed to be elicited by the activation
of chemokine receptors present in the dorsal root ganglion (DRG) neurons [53]. Dorsal root ganglion
neurons in culture are also reported to be excited by chemokines [51,54], and the excited neurons
release pain-related neurotransmitters, such as substance P and calcitonin gene-related peptide
(CGRP) [55,56]. As chemokines can excite primary afferent neurons, and recruit immune cells at
the site of nerve injury, they play an important role in simultaneously coordinating inflammation and
neuronal excitability [51–54].
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Figure 1. The immune response near the site of a nerve injury sensitizes the nerve terminals.
Resident mast cells (MC) are activated and release vasodilators that act on blood vessels,
leading to infiltration of immune cells, such as neutrophils, monocytes and T-lymphocytes.
Monocytes diff re tiate into macrophages. These immune cells release infl mmatory mediators
that sensitize termin ls of injured and uninjured nerves. Schwann cells (Sch) that cover the myelinated
nerves release cytokines (e.g., TNF-α, IL-15) that also facilitate the recruitment and activation of
macrophages. ION: Inferior orbital nerve; IAN: Inferior alveolar nerve; MC: Mast cell; T: T-lymphocyte;
N: Neutrophil; MN: Monocyte; MAC: Macrophage; TNF-α: Tumor necrosis factor alpha; IL-15:
Interleukin 15.
Accumulating evidence suggests that activated glial cells in the sensory ganglia (trigeminal ganglia
or dorsal root ganglia) and central nervous system also play a key role in neuropathic pain [16–19].
Glial cells are non-neuronal cells that provide support and protection for neurons in the central and
peripheral nervous systems [57–59]. Small satellite glial cells (SGCs) surround the cell bodies of trigeminal
ganglion and dorsal root ganglion (DRG) neurons [60]. These cells are connected by gap junctions and
are thought to have similar roles to that of astroglia, in the central nervous system [61]. The satellite
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glial cell marker, glial fibrillary acidic protein (GFAP), increases after nerve injury in the trigeminal
ganglion [62–64]. SGCs also proliferate in the trigeminal ganglion following a chronic constriction
injury of the infraorbital nerve [65]. The gap junction between them increases following trigeminal
nerve injury, along with a reduction in the pain threshold [64,66]. Expression of the major gap junction
protein, connexin 43 (Cx43), increases in the trigeminal ganglion following inferior alveolar nerve injury,
and expression is reduced by application of a selective gap junction blocker (Gap27) to the trigeminal
ganglion [64]. These findings suggest increased communication among the SGCs in the trigeminal
ganglion following nerve injury [64,66]. The close proximity of SGCs and neuronal cell bodies (Figure 2)
favors interactions by paracrine signaling and contributes to the sensitization of afferent neurons [67].
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Figure 2. Satellite glial cells (SGCs) surrounding the cell bodies of neurons in the ganglia play
an important role in the development of neuropathic pain. Nerve injury leads to the activation
and proliferation of SGCs in the sensory ganglia. They interact with neurons through paracrine
signaling. ATP, released from SGCs as well as from i jure neurons, acts on purinergic receptors,
resulting in the mutual activation of ne rons a d SGCs (indicated in the diagram by straight arrows).
Purinergic receptors, P2Y12 and P2X3, are upregulat d in the trigeminal ganglion following nerve injury.
SGCs express the inwardly rectifying potassium channel, Kir4.1, which helps to maintain extracellular
potassium homeostasis. Following nerve injury, expression of Kir4.1 is downregulated in the trigeminal
ganglion, thereby increasing extracellular potassium and neuronal excitability. Communication among
the SGCs also increases (indicated in the diagram by solid curved arrows), as evidenced by the
increase in expression of the common gap junction protein, connexin 43 (Cx43), in the trigeminal
ganglion following nerve injury. This communication spreads to the SGCs of nearby neurons, which in
turn sensitizes these cells. ATP: Adenosine triphosphate; P2Y12: Purinergic receptor subtype Y12;
P2X3: Purinergic receptor subtype X3; Kir4.1: Inwardly rectifying potassium (Kir) channel 4.1. TG:
Trigeminal gangli n.
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ATP is one of the major transmitters involved in neuron–SGC communication [68]. ATP is
released by SGCs and primary afferent neurons, which can increase the intercellular calcium
concentration [69–71]. ATP plays an important role in communication between SGCs and neurons
involving purinergic (P2) receptors (e.g., P2X and P2Y) [69–72]. Activation of the purinergic receptor,
P2Y12R, in SGCs, in the trigeminal ganglion, by ATP, increases calcium influx, which in turn
increases the excitability of the cells (Figure 2) [73–75]. Injury to the trigeminal nerve, caused by
extraction of a tooth, increases purinergic receptor P2X3 and vesicular nucleotide transporter (VNUT)
expression in the SGCs and neurons of the trigeminal ganglion, suggesting mutual activation,
possibly by VNUT-mediated ATP release [76]. ATP can be released from both trigeminal ganglion
neurons and SGCs, which allows them to reciprocally activate each other (Figure 2) [76]. Therefore,
increased communication among SGCs, and between neurons and SGCs, after peripheral nerve injury,
increases the excitability of primary afferent neurons [68,72].
SGCs in the trigeminal ganglion also play an important role in potassium ion buffering in the
ganglion [77]. Extracellular potassium homeostasis is important for maintaining neuronal excitability,
and when extracellular potassium is increased, neuronal excitability increases [78]. SGCs express
the inward-rectifying potassium channel, Kir4.1, which buffers the potassium concentration in the
trigeminal ganglion [77]. The expression of Kir4.1 is downregulated in the trigeminal ganglion
(Figure 2) following infraorbital nerve injury, and silencing Kir4.1 with siRNA induces spontaneous
and evoked facial pain-like behavior in freely moving rats [79].
The intercellular signaling between SGCs and neurons can spread to neighboring areas,
causing cross-excitation within the sensory ganglion, which might underlie extraterritorial pain
(Figure 2) [64,80]. It has been observed that injury to the mandibular nerve leads to pain-related cellular
changes, not only in neurons and SGCs of the mandibular division, but also in the maxillary and
ophthalmic divisions of the trigeminal ganglion [64,80]. Injury to the mandibular nerve also increases
the expression of Cx43 in the SGCs surrounding the neurons of the maxillary nerve, suggesting the
involvement of SGCs in the development of ectopic hypersensitivity, in the areas innervated by the
maxillary nerve, following injury to the mandibular nerve [64].
Along with the peripheral immune response, the immune response in the central nervous system
(brainstem trigeminal sensory nuclei, spinal dorsal horn) to peripheral nerve injury also plays a critical
role in neuropathic pain [16,18,19]. Microglia serve as the macrophages of the central nervous system,
are capable of phagocytosis, and play a role in the repair and scarring processes in the brain and spinal
cord, following traumatic injury [57,81]. Increased expression of the microglial markers, Iba1 and
OX-42/CD11b, in the central nervous system, following peripheral nerve injury, indicates central
activation and proliferation of microglia [82–84]. In a model of orofacial neuropathic pain, in which
injury is induced to the inferior alveolar nerve by intentional malpositioning of a dental implant
during tooth replacement, microglial activation is observed in the brainstem trigeminal subnucleus
caudalis [83]. Following nerve injury, microglia in the central nervous system can be activated
by increased primary afferent input [85,86], by immune factors from the periphery [18,87], and by
infiltrating immune cells from the circulation [88,89]. Increased activity in the primary afferents
following nerve injury not only increases postsynaptic secondary neuronal activity, but also activates
glial cells in the central nervous system (Figure 3) [85,86]. It has been observed that noxious electrical
stimulation of the peripheral nerve increases the expression of the microglial marker, Iba1, in the spinal
cord, concomitant with a decrease in pain threshold, indicating that peripheral nerve activity activates
central microglia [90,91].
Increased activity of primary afferents following nerve injury causes increased release of
neurotransmitters and neural and immune factors, such as glutamate, ATP, substance P, CGRP,
brain derived neurotrophic factor (BDNF), IL-6 and CCL2, at central terminals (Figure 3) [16,19,92].
These mediators increase the sensitivity of postsynaptic neurons and activate glial cells surrounding
the neurons. Peripherally-released immune factors, such as proinflammatory cytokines (e.g., IL-6),
might also activate central glial cells [93,94]. Peripheral IL-6 can be transported to the central nervous
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system via the circulation, and increase COX-2 activity and PGE2 release in vascular endothelial cells
of the brain, leading to a central immune response [93,94].Int. J. Mol. Sci. 2017, 18, 2051 7 of 17 
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Figure 3. Glial cell involvement in sensory nuclei participates in the development of neuropathic pain.
Microglia and astroglia are activated and proliferated in the brainstem sensory nuclei of the trigeminal
nerve. Increased primary afferent input following nerve injury causes e release of neurotransmitters
and neural and immune mediators, which increase he se sit vity of postsynaptic secondary neurons
and activate glial cells. Upon activati , glial cells release mediators (such as ATP, IL-1β, TNF-α and
BDNF) that act on secondary neurons and increase their sensitivity. Glutamate–glutamine shuttle
activity between astroglia and neurons is increased following nerve injury, thereby increasing the
glutamate supply in the synapses between primary and secondary neurons. Cx43 expression increases
in astroglia following trigeminal nerve injury, indicating increased communication among the astroglial
cells. ATP: Adenosine triphosphate; CGRP: Calcitonin gene-related peptide; BDNF: Brain derived
neurotrophic factor; IL-6: Interleukin 6; CCL2: Chemokine ligand 2; IL-1β: Interleukin 1 beta; TNF-α:
Tumor necrosis factor alpha; A: Astroglia; M: Microglia.
Infiltration of CD4 (cluster of differentiation 4)-positive T-cells into the spinal cord is observed
after spinal nerve transection [88,89]. Infiltration of macrophages or monocytes into the spinal cord
occurs following partial sciatic nerve ligation, and these cells can differentiate into microglial-like
cells [95]. Astroglia are activated subsequent to microglial activation [16,19,92]. Enhanced neuronal
activity after peripheral nerve injury can activate both astroglia and microglia (Figure 3) [16,19,92,96].
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Inhibition of nerve injury-induced neuronal activity reduces astroglial marker (GFAP) expression in
the spinal cord [96]. Upregulation of GFAP is also observed in the spinal trigeminal complex following
application of substance P or CGRP, in an ex vivo medullary slice preparation [18]. In a model of
orofacial neuropathic pain induced by inferior alveolar nerve transection, intrathecal administration of
fluoroacetate (FA)—an inhibitor of the astroglial metabolic enzyme, aconitase—attenuates nocifensive
behavior and suppresses the increase in astroglial activity, suggesting the involvement of astroglia in
pain pathogenesis [97]. Moreover, in an orofacial extra-territorial pain model (induced by injury to the
upper cervical nerve), GFAP expression is increased in the spinal trigeminal caudalis nucleus, and this
increase is suppressed by intrathecal application of FA [98].
Following nerve injury, both microglia and astroglia release chemical mediators that can sensitize
neurons in the brainstem trigeminal nucleus and spinal cord [19]. For example, ATP released
from nerve terminals and microglia following nerve injury, induces BDNF release from microglia,
by activating the purinergic receptor, P2X4. The BDNF binds to its receptor, TrkB, on nociceptive
postsynaptic neurons, inducing a shift in the chloride gradient in these cells, which in turn increases
their excitability [99,100]. IL-1β, TNF-α and ATP are key mediators, released by activated glial cells,
that sensitize neurons [18,101]. IL-1β facilitates N-methyl-D-aspartate receptor phosphorylation on
neurons, thereby changing their synaptic strength and resulting in enhanced sensitization of neurons,
which leads to behavioral hyperalgesia [18,84,102]. Astroglia also interact with neurons to regulate
synaptic activity. Glutamate, released at nerve terminals upon the arrival of nerve impulses following
nerve injury, activates metabotropic glutamate receptors on astroglia [103]. This leads to the release of
various factors by these cells, including glutamine, D-serine and ATP, which in turn modulate neuronal
activity [103].
The glutamate–glutamine shuttle between astroglia and neurons also plays a critical role in
increasing neuronal excitability after nerve injury (Figure 3) [104–106]. Astroglia uptake glutamate
that has been released into synapses, which is then synthesized into glutamine by glutamine
synthetase [104–106]. Neurons use this glutamine to produce glutamate, replenishing the glutamate
supply [104–106]. The glutamate transporter, GLT-1, is involved in transporting glutamate into
astroglia. After nerve injury, GLT-1 is downregulated, resulting in the accumulation of glutamate,
thereby increasing the excitability of postsynaptic neurons [107]. In addition, intrathecal application
of methionine sulfoximine, an inhibitor of glutamine synthetase, attenuates the elevated excitability
of neurons in the spinal trigeminal subnucleus caudalis and medullary dorsal horn, indicating the
involvement of the astroglial glutamate–glutamine shuttle in enhancing neuronal excitability [104].
Cx43 expression in astroglia increases following injury (Figure 3) to the trigeminal nerve,
and intrathecal administration of a gap junction blocker attenuates the central sensitization
of nociceptive neurons in the trigeminal subnucleus caudalis [108,109], indicating increased
communication among astroglial cells. Furthermore, activated microglia may also activate
astroglia. A recent report suggests that interleukin-18 (IL-18), a pro-inflammatory cytokine, acts as
a messenger between microglia and astroglia after peripheral nerve injury [110]. After nerve injury,
activated microglia produce IL-18 through the activation of p38 mitogen-activated protein kinases
(MAPK). Receptors for IL-18 are also increased on astroglia. The IL-18 signaling leads to the
phosphorylation of NF-κB in astroglia, which induces the activation of these cells [110].
5. Alteration of Orofacial Motor Activity in Neuropathic Pain: Glial Involvement
Chronic orofacial pain causes psychological and functional impairments [15,20,21]. Chronic pain
leads to changes in motor activity [111,112]. Chronic orofacial pain restricts jaw movement,
leading to difficulties in orofacial functions, such as mastication, swallowing, speaking and
tooth-brushing [15,111]. A study reported a four-fold increase in functional problems—such as
difficulty of chewing—in chronic orofacial pain patients, compared with the general population [15].
Limitation of jaw movements (smaller and slower movements) is observed in many experimental
pain and clinical pain studies [111,113–115]. In animal experiments, noxious stimulation of the
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orofacial structures reflexively evokes short-duration increases in jaw muscle EMG (electromyogram)
activity [116,117]. Injection of mustard oil (a small-fiber excitant and inflammatory irritant) into the
temporomandibular joint increases EMG activity in the jaw muscles [117].
Recently, we examined whether glia are involved in the alteration of orofacial motor functions
in NOP [118–120]. We demonstrated that injury to the infraorbital nerve, a sensory branch of the
trigeminal nerve, alters masticatory performance in rats [118–120]. The time for a complete masticatory
sequence (from food intake to the end of the cyclic jaw movements) was longer and the number
of complete masticatory sequences was fewer, in nerve-injured rats compared with sham-operated
rats [118]. In addition, the time taken to adequately chew food was longer, and the number of
chewing cycles was reduced, in nerve-injured rats, compared with sham-operated rats. Furthermore,
nerve-injured rats frequently dropped the food. This change in masticatory performance following
nerve injury was associated with allodynia (nocifensive behavior) in the facial skin area innervated by
the injured nerve and increased expression of the microglial marker, Iba1, in the sensory and motor
trigeminal nuclei in the brainstem [118,120]. The highest number of activated microglia was observed
on day 3 following injury (Figure 4).
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Figure 4. Temporal profile of microglial and astroglial activation in the motor nucleus of the trigeminal
nerve following peripheral nerve injury (inj-V: injury to the trigeminal nerve). Following nerve
injury, the numbers of activated microglial and astroglial cells (counted on day 3 and 14 following
nerve injury) were increased significantly compared with sham-operated rats. The highest number of
activated microglia was observed on day 3 following injury; however, the highest number of activated
astroglia was observed on day 14 following injury. The figure is modified from our previous published
papers [118,119]. * p < 0.05.
On day 14 following injury, the number of activated microglia was less than that on day 3,
but significantly more than in sham-operated rats (Figure 4). Repeated application of a microglial
inhibitor (intraperitoneal injection and microinjection into the trigeminal motor nucleus) before and
after the nerve injury restored masticatory performance to near pre-injury levels. Minocycline also
decreased the expression of microglial markers in the sensory and motor nuclei of the trigeminal
nerve, and attenuated nocifensive behavior. Many previous studies reported that microglial blockers
(e.g., minocycline) attenuated neuropathic pain, mainly by inhibiting microglial activation and
preventing the release of pro-inflammatory cytokines from microglia and other sources [121–130].
The blockers can inhibit the activation of microglia by inhibiting mitogen-activated protein (MAP)
kinase pathways [121,122]. They can inhibit the release of inflammatory mediators, like IL-1β, IL-6,
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TNFα and NO, from activated microglia [123–125]. It might be possible for the microglial blockers
to act on microglial receptors (e.g., adrenergic, dopaminergic and cholinergic, adenosine receptors)
to inhibit the release of pro-inflammatory mediators from activated microglia in neuropathic pain
conditions. They can also inhibit the trafficking of peripheral immune cells into the DRG [126].
Minocycline has been reported to inhibit the expression of major histocompatibility complex 2
(MHC II) on microglia and the subsequent reactivation and infiltration of T lymphocytes into the
CNS parenchyma [127–129]. Minocycline has also been found to inhibit the downregulation of
glial glutamate transporters’ (GTs) expression, following sciatic nerve injury, thereby, preserving the
normalized activation of N-methyl-D-aspartate (NMDA) receptors in the spinal sensory synapses [130].
The inhibition of microglial activity and attenuation of neuropathic pain behavior by microglial
blockers suggests that elevated microglial activity in the sensory and motor nuclei of the trigeminal
nerve play a pathogenetic role in orofacial motor dysfunction in neuropathic disease [118,120].
A number of previous studies have also shown activation of microglia in the trigeminal sensory
nuclei and surrounding areas following injury to the trigeminal nerve [121,131,132]. In addition,
injury to the facial and hypoglossal nerves increase microglial activity in the motor nuclei of these
nerves [133–135]. How activated microglia in the motor nucleus impact motor neuronal excitability is
not fully clear. It is possible that, similar to sensory nuclei, pro-inflammatory mediators, released by
microglia modulate the excitability of motor neurons, and thereby alter motor functions (Figure 5) [120].
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Figure 5. Schematic showing the involvement of glia in the trigeminal motor nucleus in the change in
orofacial motor activity following nerve injury. Activated microglia and astroglia are observed in the
motor trigeminal nucleus following nerve injury. Similar to sensory nuclei, pro-inflammatory mediators
might be released f m hyp r ctive microglia, and these mediators ay alter the sensitivity of motor
neurons. The astr glial glutamate–glutamine shuttle might also partici ate in the modulation of motor
neuronal activity. BDNF: Brain derived neurotrophi factor; IL-6: Interleukin 6; IL-1β: Interleukin 1 beta;
TNF-α: Tu or necrosis factor alpha; Glut: Glutamate; Gln: Glutamine; Gln sth: glutamine synthetase;
ADP: Adenosine Diphosphate; Pi: Inorganic phosphate; A: Astroglia; M: Microglia.
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We also observed increased GFAP expression in the trigeminal sensory and motor nuclei following
trigeminal peripheral nerve injury [119]. On day 3 following injury, the number of activated astroglia
in the trigeminal motor nucleus was significantly more than in sham-operated rats. However,
the highest number of activated astroglia was observed on day 14 following injury (Figure 4).
Astroglial activation was associated with an increase in the amplitude of the jaw-opening reflex,
and allodynia on facial skin. Microinjection of methionine sulfoximine, a blocker of glutamine synthetase,
decreased the amplitude of the jaw-opening reflex, which was reversed following microinjection of
glutamine into the trigeminal motor nucleus [119]. These findings suggest the involvement of the
astroglial glutamate–glutamine shuttle in orofacial motor dysfunction, following trigeminal nerve injury
(Figure 5) [119,120]. Hyperactive astroglia may produce more glutamine, which is later converted to
glutamate, which would in turn increase motor neuronal excitability (Figure 5). In addition, similar to
the sensory nucleus, other factors (e.g, ATP and ILs) released from hyperactive astroglia, may modulate
motor neuronal excitability [120]. The temporal patterns of microglial and astroglial cell activation in the
motor nucleus of the trigeminal nerve (Figure 4) show that microglia are activated earlier than astroglia
following nerve injury, similar to the findings in the sensory nucleus of the trigeminal nerve [16,19,92].
6. Conclusions
The etiology and pathophysiology of neuropathic orofacial pain are complex and diverse.
Current understanding of the pathophysiology of neuropathic orofacial pain suggests that a sequence
of events occurs during the development of neuropathic pain. Nerve injury induces immune
responses, both peripherally (around the injured area) and centrally, which play an important role
in the development and maintenance of neuropathic pain. Immune cells, glia and neurons form an
integrated network that modulates the excitability of pain pathways. Following injury, hyperactive
microglia and astroglia in the brainstem trigeminal sensory nuclei participate in the development
and maintenance of nocifensive behavior. The development of motor function impairment is an
integral event in neuropathic pain conditions. In our recent studies, we observed that hyperactive
glial cells in the brainstem trigeminal motor nucleus play a role in the modulation of orofacial
motor activity (alteration of masticatory performance and modulation of the jaw reflex). It remains
unclear how hyperactive glial cells interact with motor neurons. Pro-inflammatory mediators released
from activated glial cells may affect the excitability of motor neurons. Changes in the astroglial
glutamate–glutamine shuttle might also be involved in the modulation of the jaw reflex in neuropathic
conditions. Future studies on the interaction between glial cells and motor neurons should advance
our understanding of the pathogenesis of neuropathic pain.
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